TSR1 and prostate cancer: Finally, ADAMTS5's recombinant TSR1 inhibits the growth of melanoma in mice by anti-angiogenesis mechanism (32), and ADAMTS5 can also be used as a prognostic biomarker for prostate cancer (33).